Browse

Belotecan, new camptothecin analogue, is active in patients with small-cell lung cancer: results of a multicenter early phase II study

Cited 35 time in Web of Science Cited 35 time in Scopus
Authors
Lee, D H; Kim, S-W; Suh, C; Lee, J-S; Lee, J H; Lee, S-J; Ryoo, B Y; Park, K; Kim, J S; Heo, D S; Kim, N K
Issue Date
2007-09-08
Publisher
Oxford University Press
Citation
Ann Oncol. 2008 Jan;19(1):123-7. Epub 2007 Sep 6.
Keywords
AgedAntineoplastic Agents, Phytogenic/pharmacokinetics/*therapeutic useAntineoplastic Combined Chemotherapy Protocols/therapeutic useCamptothecin/adverse effects/*analogs &derivatives/pharmacokinetics/therapeutic useCarcinoma, Small Cell/*drug therapyDNA Topoisomerases, Type I/antagonists & inhibitorsDisease-Free SurvivalFemaleHumansLung Neoplasms/*drug therapyMaleMiddle AgedNeoplasm Proteins/antagonists & inhibitorsNeutropenia/chemically inducedSalvage TherapyTreatment Outcome
Abstract
BACKGROUND: Belotecan (Camtobell, Chong Keun Dang Corp, Seoul, Korea; CKD602) is a new camptothecin analogue. This study aimed to investigate the safety and efficacy of single-agent belotecan for small-cell lung cancer (SCLC). PATIENTS AND METHODS: Twenty-seven patients with chemotherapy-naive or chemosensitive SCLC were treated with belotecan 0.5 mg/m(2)/day on days 1-5 of a 3-week cycle. All 27 patients were assessable for toxicity, and 21 patients assessable for response. RESULTS: Nine patients (42.9%) showed objective tumor responses including one complete response; seven (63.6%) in 11 chemotherapy-naive patients; and two (20.0%) in 10 chemosensitive patients. With a median follow-up of 5 years, median progression-free and survival time for chemotherapy-naive patients were 4.8 months and 11.9 months, respectively, while the corresponding values for chemosensitive patients were 3.3 months and 10.5 months, respectively. The most common toxicity was neutropenia. CONCLUSION: Belotecan was active in SCLC patients as a single agent, warranting further investigations of belotecan in combination with platinum or other active agents.
ISSN
1569-8041 (Electronic)
Language
English
URI
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17823384

http://hdl.handle.net/10371/29577
DOI
https://doi.org/10.1093/annonc/mdm437
Files in This Item:
There are no files associated with this item.
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Program in Cancer Biology (협동과정-종양생물학전공)Journal Papers (저널논문_협동과정-종양생물학전공)
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse